2. GPCR/G Protein Neuronal Signaling Stem Cell/Wnt MAPK/ERK Pathway Apoptosis Immunology/Inflammation Metabolic Enzyme/Protease
  3. Melatonin Receptor ERK TNF Receptor Interleukin Related MMP Endogenous Metabolite
  4. 5-Methoxytryptophol

5-Methoxytryptophol is a 5-methoxyindole alcohol structurally homologous to Melatonin (HY-B0075). It is secreted by the mammalian pineal gland and exhibits an inverse circadian rhythm. 5-Methoxytryptophol regulates bone metabolism by activating the ERK1/2 pathway. It reduces the levels of pro-inflammatory cytokines TNF-α and IL-1β, as well as proteolytic enzymes MMP-1 and MMP-2, in serum and dental pulp tissues, thereby ameliorating acute pulpitis. 5-Methoxytryptophol induces rapid sleep in mice, while high doses cause respiratory depression and death. 5-Methoxytryptophol. 5-Methoxytryptophol can be used in studies related to acute pulpitis, hypnosis, and bone metabolism.

For research use only. We do not sell to patients.

5-Methoxytryptophol

5-Methoxytryptophol Chemical Structure

CAS No. : 712-09-4

Size Price Stock Quantity
Solid or liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid or liquid
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of 5-Methoxytryptophol:

5-Methoxytryptophol Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE 5-Methoxytryptophol

View All Melatonin Receptor Isoform Specific Products:

View All Isoforms
MT1 MT2

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

View All MMP Isoform Specific Products:

View All Isoforms
MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms
Human Endogenous Metabolite Microbial Metabolite

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

5-Methoxytryptophol is a 5-methoxyindole alcohol structurally homologous to Melatonin (HY-B0075). It is secreted by the mammalian pineal gland and exhibits an inverse circadian rhythm. 5-Methoxytryptophol regulates bone metabolism by activating the ERK1/2 pathway. It reduces the levels of pro-inflammatory cytokines TNF-α and IL-1β, as well as proteolytic enzymes MMP-1 and MMP-2, in serum and dental pulp tissues, thereby ameliorating acute pulpitis. 5-Methoxytryptophol induces rapid sleep in mice, while high doses cause respiratory depression and death. 5-Methoxytryptophol. 5-Methoxytryptophol can be used in studies related to acute pulpitis, hypnosis, and bone metabolism[1].

IC50 & Target

Human Endogenous Metabolite

 

In Vitro

5-Methoxytryptophol (0.001-2.5 mM; 24 h) slightly reduces the metabolic activity of MC3T3-E1 preosteoblasts[2].
5-Methoxytryptophol (0.001-2.5 mM; 48 h) exhibits cytotoxicity against MC3T3-E1 preosteoblasts at concentrations of 1 mM and 2.5 mM, while doses of 0.001 mM and 0.01 mM exert protective effects[2].
5-Methoxytryptophol (0.001-2.5 mM; 14 days) reduces the total RNA content of MC3T3-E1 preosteoblasts at the concentration of 2.5 mM[2].
5-Methoxytryptophol (0.001-1 mM; 14 days) reduces Rankl mRNA expression in MC3T3-E1 preosteoblasts in a dose-dependent manner (with a stronger inhibitory effect at low doses than melatonin), and decreases Opg mRNA expression at concentrations of 0.1 and 1 mM[2].
5-Methoxytryptophol (0.1 mM; 14 days) significantly promotes osteocalcin secretion by MC3T3-E1 preosteoblasts[2].
5-Methoxytryptophol (0.1 mM; 14 days) enhances the mineralization of MC3T3-E1 preosteoblasts[2].
5-Methoxytryptophol (0.1 mM; 5 days) inhibits the formation of multinucleated TRAP-positive osteoclasts in RANKL-stimulated RAW264.7 preosteoclasts[2].
5-Methoxytryptophol (0.1 mM; 5 days) reduces the mRNA expression of Mmp-9 and CtsK in RANKL-stimulated RAW264.7 preosteoclasts, without altering the mRNA level of Trap[2].
5-Methoxytryptophol (0.1 mM; 5 days) inhibits the bone resorption activity of RANKL-stimulated RAW264.7 preosteoclasts on dentin slices[2].
5-Methoxytryptophol (0.1 mM; 2 h) activates the ERK1/2 pathway in MC3T3-E1 osteoprogenitor cells and RAW264.7 preosteoclasts (by upregulating the expression of phosphorylated ERK1/2), and this activation is inhibited by pretreatment with the melatonin receptor antagonist luzindole (HY-101254)[2].
5-Methoxytryptophol (0.01-10 mM; 50 min) inhibits lipid peroxidation in rat liver microsomal membranes, with an IC50 of 0.7 mM. Concentrations of 0.01-3 mM dose-dependently maintain membrane fluidity against oxidative stress, while the 10 mM concentration, although capable of inhibiting lipid peroxidation, fails to prevent membrane rigidification[4].
5-Methoxytryptophol (0.01-10 mM; 30 min) reduces the membrane fluidity of rat liver microsomal membranes at concentrations of 0.3-10 mM, and does not alter the level of lipid peroxidation in the absence of oxidative stress[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

5-Methoxytryptophol Related Antibodies

Cell Viability Assay[2]

Cell Line: MC3T3-E1 preosteoblastic cells
Concentration: 0.001 mM, 0.01 mM, 0.1 mM, 1 mM, 2.5 mM
Incubation Time: 24 h
Result: Slightly reduced metabolic activity of MC3T3-E1 cells compared to vehicle control.
Showed a dose-response effect.

Cell Cytotoxicity Assay[2]

Cell Line: MC3T3-E1 preosteoblastic cells
Concentration: 0.001 mM, 0.01 mM, 0.1 mM, 1 mM, 2.5 mM
Incubation Time: 48 h
Result: Produced significantly higher LDH release at 2.5 mM and 1 mM compared to control, indicating cytotoxicity.
Showed lower LDH release at 2.5 mM than 2.5 mM melatonin.
Reduced cell death by ≤5% at 0.001 mM and 0.01 mM doses, showing a protective effect.

Real Time qPCR[2]

Cell Line: MC3T3-E1 preosteoblastic cells
Concentration: 0.001 mM, 0.01 mM, 0.1 mM, 1 mM
Incubation Time: 14 days
Result: Significantly decreased Rankl mRNA expression at all tested doses compared to control, with a dose-response effect where higher doses caused greater inhibition.
Decreased Rankl expression more than equivalent doses of melatonin at 0.001-0.1 mM doses.
Significantly decreased Opg mRNA expression at 0.1 mM and 1 mM compared to control.

Real Time qPCR[2]

Cell Line: RAW264.7 preosteoclastic cells
Concentration: 0.1 mM (with 4 ng/mL RANKL co-treatment)
Incubation Time: 5 days
Result: Did not significantly change Trap mRNA levels compared to RANKL-only control.
Significantly decreased mRNA levels of functional osteoclast markers Mmp-9 and CtsK.

Immunofluorescence[2]

Cell Line: MC3T3-E1 preosteoblastic cells, RAW264.7 preosteoclastic cells
Concentration: 0.1 mM (with 0.1 mM luzindole pre-treatment for 2 h)
Incubation Time: 2 h
Result: Increased phospho-ERK1/2 expression in both MC3T3-E1 and RAW264.7 cells to a greater degree than melatonin and vehicle control.
Pre-treatment with luzindole significantly reduced phospho-ERK1/2 expression induced by 5-MTX.
In Vivo

5-Methoxytryptophol (5 mg/kg; i.p.; single dose) significantly reduces proinflammatory cytokine and matrix metalloproteinase levels in serum and pulp tissue, and improves histopathological outcomes in a rat model of lipopolysaccharide-induced acute pulpitis[1].
5-Methoxytryptophol (200-700 mg/kg; i.p.; single dose) induces rapid-onset sleep in healthy CD-1 mice, with mean sleep duration ranging from 5.2 min at 300 mg/kg to 43.9 min at 600 mg/kg, and an acute LD50 of about 750 mg/kg[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Wistar albino rats (male and female, 200-250 g, lipopolysaccharide-induced acute pulpitis)[1]
Dosage: 5 mg/kg
Administration: i.p.; single dose
Result: Reduced serum and pulp tissue levels of TNF-α, IL-1β, MMP-1, and MMP-2 significantly compared to the untreated acute pulpitis group.
Showed considerable histopathological improvement compared to the untreated acute pulpitis group: 50% of samples had inflammatory reaction restricted to the 60-67.5 degree region of the pulp cavity (score 4), 12.5% had inflammatory infiltrate intensity scores of 2 (20-40 cells), 50% had scores of 3 (40-60 cells), 37.5% had scores of 4 (over 60 cells), 100% had persistent inflammatory edema, 87.5% had pulp necrosis restricted to 20-30% of the 45-105 degree area (score 3), and 12.5% had over 30% necrosis (score 4).
Animal Model: CD-1 (4-6 weeks old, 16-30 grams)[3]
Dosage: 200 mg/kg; 300 mg/kg; 400 mg/kg; 500 mg/kg; 600 mg/kg; 700 mg/kg
Administration: i.p.
Result: Showed 0 out of 6 mice slept, with 0 min sleep onset and duration at 200 mg/kg.
Induced sleep in 5 out of 6 mice, with a mean sleep onset of 2.0 min and mean sleep duration of 5.2 min at 300 mg/kg.
Induced sleep in 4 out of 6 mice, with a mean sleep onset of 1.8 min and mean sleep duration of 13.8 min at 400 mg/kg.
Induced sleep in 5 out of 6 mice, with a mean sleep onset of 1.3 min and mean sleep duration of 16.3 min at 500 mg/kg.
Induced sleep in 5 out of 6 mice, with a mean sleep onset of 1.3 min and mean sleep duration of 43.9 min at 600 mg/kg.
Induced sleep in 4 out of 6 mice (2 mice died during observation), with a mean sleep onset of 1.2 min and mean sleep duration of 38.5 min at 700 mg/kg.
Exhibited an acute LD50 of about 750 mg/kg.
Molecular Weight

191.23

Formula

C11H13NO2
CAS No.
Appearance

Viscous Liquid

Color

Colorless to light yellow

SMILES

OCCC1=CNC2=C1C=C(OC)C=C2
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (522.93 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 5.2293 mL 26.1465 mL 52.2930 mL
5 mM 1.0459 mL 5.2293 mL 10.4586 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (13.07 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (13.07 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.95%

SDS (393 KB)

COA (248 KB) HNMR (232 KB) LCMS (84 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 5.2293 mL 26.1465 mL 52.2931 mL 130.7326 mL
5 mM 1.0459 mL 5.2293 mL 10.4586 mL 26.1465 mL
10 mM 0.5229 mL 2.6147 mL 5.2293 mL 13.0733 mL
15 mM 0.3486 mL 1.7431 mL 3.4862 mL 8.7155 mL
20 mM 0.2615 mL 1.3073 mL 2.6147 mL 6.5366 mL
25 mM 0.2092 mL 1.0459 mL 2.0917 mL 5.2293 mL
30 mM 0.1743 mL 0.8716 mL 1.7431 mL 4.3578 mL
40 mM 0.1307 mL 0.6537 mL 1.3073 mL 3.2683 mL
50 mM 0.1046 mL 0.5229 mL 1.0459 mL 2.6147 mL
60 mM 0.0872 mL 0.4358 mL 0.8716 mL 2.1789 mL
80 mM 0.0654 mL 0.3268 mL 0.6537 mL 1.6342 mL
100 mM 0.0523 mL 0.2615 mL 0.5229 mL 1.3073 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

5-Methoxytryptophol Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

5-Methoxytryptophol712-09-4Melatonin ReceptorERKTNF ReceptorInterleukin RelatedMMPEndogenous MetaboliteExtracellular signal regulated kinasesTumor Necrosis Factor ReceptorTNFRILMatrix metalloproteinasesMMP-2TNF-αMC3T3-E1 preosteoblastic cellsmelatonin receptor (MT1/MT2)MMP-1acute pulpitisIL-1βpineal glandERK1/2 pathwayRAW264.7 preosteoclastic cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
5-Methoxytryptophol
Cat. No.:
HY-113440
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.